Abbisko Cayman Ltd 02256
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 3.13
- Day Range
- HKD 3.13–3.28
- 52-Week Range
- HKD 2.05–4.69
- Bid/Ask
- HKD 3.26 / HKD 3.28
- Market Cap
- HKD 2.09 Bil
- Volume/Avg
- 1.5 Mil / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 95.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.68%
Company Profile
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 218
- Website
- https://www.abbisko.com
Comparables
Valuation
|
Metric
|
02256
|
02171
|
06628
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.98 | 1.66 | 0.77 |
Price/Sales | 95.43 | — | 12.16 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
02256
|
02171
|
06628
|
|---|---|---|---|
Quick Ratio | 18.50 | 9.49 | 1.50 |
Current Ratio | 18.70 | 9.55 | 1.61 |
Interest Coverage | −228.07 | −174.85 | −33.53 |
Quick Ratio
02256
02171
06628
Profitability
|
Metric
|
02256
|
02171
|
06628
|
|---|---|---|---|
Return on Assets (Normalized) | −16.58% | −28.70% | −22.79% |
Return on Equity (Normalized) | −18.39% | −35.29% | −38.31% |
Return on Invested Capital (Normalized) | −20.09% | −35.38% | −26.22% |
Return on Assets
02256
02171
06628
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zwzxqgjwpl | Gxgh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dqhblvswv | Jmyjrw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jzvkbslcz | Bdpfzr | $97.8 Bil | |
MRNA
| Moderna Inc | Ysxnynrd | Cxf | $41.3 Bil | |
ARGX
| argenx SE ADR | Jftfltvz | Wvj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rqfvfbzg | Vxp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zzxvvdtps | Cjjmz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mcxdjkdn | Bwmgbjn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dmclxkckdl | Jxkml | $12.5 Bil | |
INCY
| Incyte Corp | Msjvvxvv | Gkdjph | $11.6 Bil |